Highlights

  • September-quarter Australian sales Revenue increased 6% YoY to AUD 3.6 million.
  • Gross profit rose 27% YoY and gross Margin expanded from 35% to 42%.
  • The company completed its US divestment and signed a conditional all-scrip Acquisition agreement for Vitable.

Elixinol Wellness Limited (ASX:EXL) reported several developments in its latest company disclosure. September-quarter Australian sales revenue increased 6% YoY to AUD 3.6 million. Gross Profit rose 27% YoY and gross margin expanded from 35% to 42%. Its operational updates also cover the implications for future activity, financing or commercial execution. The most relevant distinctions are between completed results and actions that remain proposed or subject to further work. The company’s next reporting period will provide a basis to assess which of those priorities have progressed.

Sales mix and profitability

Elixinol reported third-quarter 2026 revenue of AUD 3.6 million from its continuing Australian business, up 6% YoY. Gross profit increased 27% YoY to AUD 1.5 million, with gross margin improving to 42% from 35% in the prior corresponding quarter. The company attributed the change to its product and channel mix and a greater focus on higher-margin revenue.

Growth in gross profit outpaced sales, making profitability of the remaining operations an important feature of the quarter. The reporting basis excludes the divested US business, so the comparison relates to the continuing Australian activities.

Brand performance and distribution

The Healthy Chef generated AUD 0.87 million revenue, up 13% YoY, with gross profit of AUD 0.52 million at a 60% margin. The company reported expanded pharmacy distribution for this brand. Australian Primary Hemp ingredients revenue rose 81% YoY. Mt Elephant also began distributing its Cake Pods range through more than 700 supermarkets.

These developments provide several product-level drivers rather than reliance on one distribution channel. Their contribution to future group margins will depend on sell-through, product costs and repeat orders.

Operating cash versus adjusted measures

Operating expenses declined 26% YoY. Elixinol disclosed a reported September-quarter net operating cash outflow of approximately AUD 0.32 million, while its separately defined underlying Operating Cash Flow was positive by about AUD 0.04 million. Management described this as the fourth consecutive quarter of positive underlying operating cash flow. Cash at 30 September was AUD 0.9 million.

The underlying figure excludes particular financing, tax and non-recurring items and should not be mistaken for statutory cash flow. Both measures are relevant to assessing Liquidity following the portfolio changes.

Acquisition and portfolio simplification

Elixinol completed the disposal of its US Business in September 2026 and signed a conditional agreement to acquire personalised supplement subscription platform Vitable through an all-scrip transaction. The company said the combination could exceed AUD 20 million in annual revenue on a pro forma 2026 basis; Shareholder approval remained outstanding.

The proposed acquisition broadens the subscription element of the business, but the transaction and projected combined scale are conditional. Integration, margins and actual cash generation remain important execution measures.

Key Insights

The central development for Elixinol Wellness Limited (ASX:EXL) is the relationship between its latest disclosed results and the next operational steps. The reported figures provide a factual baseline, while the stated objectives remain subject to spending decisions, timing and execution. Company-specific milestones, rather than assumptions about market trading, will determine how subsequent reporting can be evaluated.